Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 15 August 2022, 16:50 HKT/SGT

Source: Legend Capital
Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully

HONG KONG, Aug 15, 2022 - (ACN Newswire) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange. R&G Pharmastudies publicly issued 15,000,000 shares at a price of RMB78.88 per share, and the total amount of funds raised is expected to be RMB1.18 billion.

R&G PharmaStudies is a large-scale professional clinical trial outsourcing service supplier in China. It has established a complete set of pharmaceutical R&D outsourcing service systems covering the whole chain of clinical trials. R&G PharmaStudies provides integrated services throughout the entire process of clinical trials with its comprehensive drug R&D service system; the main services offered by the company cover clinical trial operation services, clinical trial site management services, biological sample testing services, data management, and statistical analysis services, clinical trial consulting services, clinical pharmacology services, etc. R&G PharmaStudies is committed to providing high-quality and efficient clinical research services in line with international standards. With a broad and high-quality customer base, it has provided professional services for about 750 Chinese and foreign pharmaceutical companies.

Legend Capital invested in the Series A round of R&G PharmaStudies in the second half of 2017 and has kept on supporting the development of R&G PharmaStudies. Jafar Wang, the Co-Chief Investment Officer of Legend Capital, said, "Congratulations on the successful listing of R&G PharmaStudies! R&G PharmaStudies is a veteran of China's pharmaceutical clinical CRO industry and has long provided full-chain clinical CRO services for Chinese and foreign innovative pharmaceutical enterprises. The successful listing will be the starting point of the new long run of R&G PharmaStudies; with its global vision, well-known expert team, and high-quality service system, we are optimistic about the long-term development potential of R&G PharmaStudies, and look forward to the continuous growth of the company."

Legend Capital has a systematic layout in CRO/CDMO. In addition to R&G PharmaStudies, Legend Capital has invested in plenty of other new-drug R&D CRO/CDMO companies, such as WuXi Apptec, WuXi Biologics, Pharmaron, Bellen, ClinChoice, SAFE Pharmaceutical, dMed Biopharmaceutical, XiHua Scientific, BirdoTech, Intellective Biologics, Biortus, and Simoon Record.

About Legend Capital

Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit and follow us on LinkedIn @Legend Capital (

Topic: Press release summary
Source: Legend Capital

Sectors: Healthcare & Pharm, PE, VC & Alternatives, Clinical Trials
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Legend Capital
Sept 25, 2022 10:56 HKT/SGT
GalaxySpace Completes a New Financing Round with Legend Capital Re-upped
Sept 25, 2022 10:47 HKT/SGT
Leadrive Technology Completes Series C Financing, Legend Capital Re-upped
Sept 2, 2022 17:05 HKT/SGT
Legend Capital: The Logic of Technology Investment Has Changed
Aug 19, 2022 17:55 HKT/SGT
Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY
Aug 9, 2022 13:06 HKT/SGT
Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully
Aug 8, 2022 13:46 HKT/SGT
New Power to Legend Capital Carbon Neutral Investment Portfolio: Ruicycle Raises Over RMB 300 Million from Series B
July 28, 2022 12:16 HKT/SGT
Led by Legend Capital, The Leading Intelligent Special Robot Company AKA Robotics Completes Series A Financing
July 21, 2022 17:20 HKT/SGT
Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully
July 7, 2022 19:13 HKT/SGT
Co-led by Legend Capital, Huili Biotechnology Completes Series A Financing Round with Hundreds of Million RMB
June 16, 2022 11:00 HKT/SGT
Legend Capital Increases Carbon Neutrality Investments: Portfolio Company Talent New Energy Completes A++ Financing Round with Several Hundred Million RMB
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: